Derived From Bacteria Patents (Class 435/220)
-
Patent number: 8871445Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: GrantFiled: April 23, 2014Date of Patent: October 28, 2014Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Le Cong, Feng Zhang
-
Publication number: 20140314716Abstract: The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metallopro teases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.Type: ApplicationFiled: August 2, 2012Publication date: October 23, 2014Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC, OF DEPT OF HEALTH AND HUMAN SERVICESInventors: Andrei P. Pomerantsev, Stephen H. Leppla
-
Patent number: 8865406Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.Type: GrantFiled: March 24, 2014Date of Patent: October 21, 2014Assignees: The Broad Institute Inc., Massachusetts Institute of TechnologyInventors: Feng Zhang, Fei Ran
-
Publication number: 20140308267Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventors: Michael Schmidt, Jurge Frevert, Fred Hofmann, Gerhard Groer
-
Publication number: 20140308266Abstract: The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventor: Karl-Heinz Eisele
-
Publication number: 20140302006Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: ApplicationFiled: April 11, 2014Publication date: October 9, 2014Applicant: Syntaxin LimitedInventors: Steven JOHNSTONE, Philip MARKS, Keith FOSTER
-
Publication number: 20140302004Abstract: Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live Staphylococcus aureus from many growth phases i.e. stationary, logarithmic and biofilm growth. The recombinant triple fusion protein comprising the three functional antimicrobial domains is designed to be refractory to resistance development.Type: ApplicationFiled: March 18, 2013Publication date: October 9, 2014Applicant: The United Sates of America, as represented by the Secretary of AgricultureInventor: The United Sates of America, as represented by the Secretary of Agriculture
-
Patent number: 8841111Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: March 18, 2013Date of Patent: September 23, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8841110Abstract: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.Type: GrantFiled: February 28, 2013Date of Patent: September 23, 2014Assignee: Allergan, Inc.Inventors: Hui Xiang, Mingjiang Luo, Ping Wang, Stephen Donovan
-
Publication number: 20140255550Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.Type: ApplicationFiled: May 23, 2014Publication date: September 11, 2014Applicant: Novozymes A/SInventors: Leonardo De Maria, Carsten Andersen, Lars Lehmann Hyllling Christensen, Soren Flensted Lassen, Peter Rahbek Ostergaard
-
Publication number: 20140227738Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: September 21, 2012Publication date: August 14, 2014Applicant: Novozymes A/SInventors: Jeppe Wegener Tams, Tine Hoff, Morten Gjermansen, Peter Rahbek Oestergaard, Robert Piotr Olinski, Katrine Pontoppidan, Carsten Sjoeholm
-
Patent number: 8795965Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: GrantFiled: February 18, 2014Date of Patent: August 5, 2014Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Patent number: 8778338Abstract: A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.Type: GrantFiled: March 14, 2008Date of Patent: July 15, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jonathan David Gass, Chaitan Khosla, Michael Bethune, Matthew John Siegel
-
Patent number: 8771945Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.Type: GrantFiled: February 18, 2014Date of Patent: July 8, 2014Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Patent number: 8765441Abstract: The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to Streptomyces sp., or a strain derived therefrom, which produces a protease capable of efficiently decomposing proteins recalcitrant to proteolysis as contained in waste water, organic waste liquids, industrial wastes and so forth.Type: GrantFiled: August 9, 2011Date of Patent: July 1, 2014Assignee: Microbial Chemistry Research FoundationInventors: Hiroyasu Doi, Naoko Kinoshita, Tatsuzo Oka, Zhao Hui
-
Patent number: 8765471Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.Type: GrantFiled: April 15, 2013Date of Patent: July 1, 2014Assignee: Nordmark Arzneimittel GmbH & Co. KGInventors: Manfred Kurfuerst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
-
Publication number: 20140178966Abstract: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: Allergan, Inc.Inventor: Hui Xiang
-
Patent number: 8748151Abstract: The invention relates to a polypeptide comprising: (a) a HC-domain or fragment thereof of the neurotoxic component of a clostridial toxin; and (b) a first LC domain or fragment thereof of the neurotoxic component of a clostridial toxin; and (c) at least one further LC domain or fragment thereof of the neurotoxic component of a clostridial toxin wherein the first and the at least one further LC domain may be the same or different from each other, and wherein each of said fragments of said first and of said at least one further LC domain still exhibits proteolytic activity.Type: GrantFiled: August 28, 2009Date of Patent: June 10, 2014Assignee: Merz Pharma GmbH & Co. KGaAInventor: Jurgen Frevert
-
Therapeutic Use of Botulinum Neurotoxin in the Treatment of pain associated with diabetic neuropathy
Publication number: 20140154781Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: IPSEN PHARMA S.A.S.Inventors: Christine FAVRE, Michel AUGUET, Piere-Etienne CHABRIER DE LASSAUNIERE -
Publication number: 20140147550Abstract: The invention relates to a method of supplementing farm animal feed with an enzymatic complex including a mixture of proteases, obtained by culturing a Streptomyces fradiae strain, wherein among this mixture of proteases one of them has an isoelectric point of around 7.0 and another has an isoelectric point of around 8.0. The invention also relates to feed compositions for farm animals including the enzymatic complex as well as the manufacturing process enzymatic complex thereof.Type: ApplicationFiled: November 26, 2013Publication date: May 29, 2014Inventor: Dominique HOOREMAN
-
Publication number: 20140127783Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: ApplicationFiled: November 21, 2013Publication date: May 8, 2014Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20140127784Abstract: The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins.Type: ApplicationFiled: January 2, 2014Publication date: May 8, 2014Applicant: Allergan, Inc.Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
-
Publication number: 20140106457Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.Type: ApplicationFiled: September 23, 2013Publication date: April 17, 2014Inventors: Steen Troels Jorgensen, Poul Erik Pedersen
-
Patent number: 8697414Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: August 16, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8697359Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.Type: GrantFiled: October 15, 2013Date of Patent: April 15, 2014Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Patent number: 8697413Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: August 16, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8685693Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: March 18, 2013Date of Patent: April 1, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8685392Abstract: The invention relates to glutamine endopeptidase enzymes from Rothia spp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.Type: GrantFiled: October 7, 2010Date of Patent: April 1, 2014Assignee: Trustees of Boston UniversityInventors: Eva J. Helmerhorst, Frank G. Oppenheim
-
Patent number: 8685692Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: March 18, 2013Date of Patent: April 1, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20140072549Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.Type: ApplicationFiled: April 20, 2012Publication date: March 13, 2014Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
-
Publication number: 20140057317Abstract: Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes. Kits comprising materials, reagents, and cells for carrying out the directed evolution methods described herein are also provided.Type: ApplicationFiled: June 20, 2013Publication date: February 27, 2014Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, Irwin Chen, Brent M. Dorr
-
Publication number: 20140017763Abstract: Proteases encompassing an amino acid sequence, which are at least 70% identical to the amino acid sequence specified in SEQ ID NO. 1 over the entire length thereof and which, in the listing according to SEQ ID NO. 1, have the amino acid substitution I21V in combination with at least one further amino acid substitution, the further amino acid substitution being selected from the group consisting of Q12L, M122L, N177V, A222S, V228I and T247N, and agents encompassing such proteases, exhibit very good cleaning performance on egg-containing stains.Type: ApplicationFiled: September 9, 2013Publication date: January 16, 2014Applicant: HENKEL AG & CO. KGAAInventors: Susanne Wieland, Petra Siegert, Timothy O'Connell, Karl-Heinz Maurer, Ronny Martinez, Ulrich Schwaneberg, Hendrik Hellmuth
-
Publication number: 20140004094Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: December 13, 2012Publication date: January 2, 2014Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock, Bo Yu, Thomas L. Wegman
-
Publication number: 20140005094Abstract: The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.Type: ApplicationFiled: May 6, 2013Publication date: January 2, 2014Applicant: Danisco US Inc.Inventors: Wolfgang Aehle, David A. Estell, Ronaldus W.J. Hommes, Brian E. Jones, Marc Kolkman, Chris Leeflang, Hiroshi Oh, Ayrookaran J. Poulose, Andrew Shaw, Wilhelmus A.H. Van der Kley, Leonardus P.M. Van Marrewijk
-
Publication number: 20130344055Abstract: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive.Type: ApplicationFiled: December 23, 2011Publication date: December 26, 2013Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, LYSANDO AGInventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
-
Publication number: 20130336974Abstract: The invention provides compositions and methods for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic cell. The bioactive moiety is linked to an A component of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate or mimetic. For delivery, the cell is contacted with the linked bioactive moiety and a corresponding B component of the bacterial toxin or a functional fragment thereof.Type: ApplicationFiled: January 10, 2012Publication date: December 19, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Robert J. Collier, Brad L. Pentelute
-
Patent number: 8609087Abstract: Compounds and methods for designing and identifying compounds which inhibit TFPP-like aspartyl protease enzymes by targeting the aspartic acid residues of the active site or mimicking peptides corresponding to the region surrounding the substrate's cleavage site are provided. Agents identified as inhibitors of TFPP-like aspartyl proteases such as type 4 prepilin peptidases are expected to be useful as anti-bacterial agents and in inhibiting development of drug resistant strains of bacteria.Type: GrantFiled: March 4, 2005Date of Patent: December 17, 2013Assignee: Trustees of Dartmouth CollegeInventors: Ronald K. Taylor, Christian F. LaPointe
-
Publication number: 20130330807Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: ApplicationFiled: August 16, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20130330758Abstract: At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.Type: ApplicationFiled: February 20, 2012Publication date: December 12, 2013Applicant: KOREA FOOD RESEARCH INSTITUTEInventors: Nam-Soo Kim, Chong-Tai Kim, Yong-Jin Cho, Chul-Jin Kim, Jin-Soo Maeng, Soo-Jin Kwon
-
Publication number: 20130330806Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: ApplicationFiled: August 16, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20130323815Abstract: The invention provides methods for extraction of fungal (e.g., yeast spp., filamentous fungal spp.) nucleic acid (e.g., DNA, RNA) from a sample (e.g., be human or veterinary clinical or research samples, agricultural samples, agricultural commodity samples, food products, or environmental samples). In some embodiments, the present invention provides enhanced nucleic acid extraction from samples comprising fungal cell(s) wherein enzymatic (e.g., lysostaphin treatment, lyticase treatment) sample treatment is performed in combination with mechanical (e.g., bead beating) sample treatment.Type: ApplicationFiled: September 23, 2011Publication date: December 5, 2013Applicant: IBIS BIOSCIENCES, INC.Inventors: Gerard Gundling, Thomas Laffler, Cristina A. Ivy, Lendell Cummins
-
Publication number: 20130288336Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.Type: ApplicationFiled: July 15, 2013Publication date: October 31, 2013Inventors: Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
-
Publication number: 20130281360Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.Type: ApplicationFiled: August 31, 2011Publication date: October 24, 2013Applicant: The Scipps Research InstituteInventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
-
Publication number: 20130273633Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: ApplicationFiled: March 18, 2013Publication date: October 17, 2013Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20130259826Abstract: Embodiments herein report compositions, methods and uses for inducing an innate immune response in a subject. Embodiments herein also generally report compositions, methods and uses for bacterial-derived peptides to induce an innate immune response in a subject having a bacterial or viral disorder and/or cancer. In certain embodiments, compositions herein concern derivatives of p60 protein of Listeria monocytogenes.Type: ApplicationFiled: November 10, 2010Publication date: October 3, 2013Inventors: Laurel L. Lenz, Rebecca L. Schmidt
-
Patent number: 8546108Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.Type: GrantFiled: January 24, 2011Date of Patent: October 1, 2013Assignee: Allergan, Inc.Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
-
Patent number: 8530205Abstract: The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method.Type: GrantFiled: June 16, 2011Date of Patent: September 10, 2013Assignee: IL Dong Pharm Co., Ltd.Inventors: Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang
-
Patent number: 8530217Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: GrantFiled: December 16, 2009Date of Patent: September 10, 2013Assignee: Novo Nordisk A/SInventors: Inga Sig Nielsen Nørby, Lars Fogh Iversen
-
Patent number: 8512992Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: May 20, 2011Date of Patent: August 20, 2013Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: RE45074Abstract: The present invention provides a method of pretreating a sample containing a glycated amine as an analyte, thereby enabling highly reliable measurement of a glycated amine. A glycated amino acid in the sample is degraded by causing a fructosyl amino acid oxidase (FAOD) to act thereon, and thereafter, a FAOD further is caused to act on the glycated amine as the analyte in the sample to cause a redox reaction. The amount of the glycated amine is determined by measuring the redox reaction. The substrate specificity of the FAOD caused to act on the glycated amino acid may be either the same as or different from that of the FAOD caused to act on the glycated amine. When using the same FAOD, a FAOD is caused to act on the glycated amino acid to degrade it, and thereafter, the sample is treated with a protease to inactivate the FAOD and also to degrade the glycated amine.Type: GrantFiled: October 16, 2012Date of Patent: August 12, 2014Assignee: ARKRAY, Inc.Inventors: Satoshi Yonehara, Tsuguki Komori